History of Snakebite Envenomation Treatment and Contribution of Turkey to Global Antivenom Production

Can Sarica1, Leyla Topcu Sarica2, Tarik Ozturk2, Ruslan Abdullayev2

1Department of Neurosurgery, Health Sciences University Adiyaman Training and Research Hospital, Adiyaman, Turkey
2Department of Anesthesiology and Reanimation, Health Sciences University Adiyaman Training and Research Hospital, Adiyaman, Turkey


Have you ever treated a case of human envenoming in the emergency department? If yes, did you pay attention to the origin of the antivenom used? Not so long ago, for until about a decade, we used to import antivenoms from various countries such as Egypt and Serbia. Antivenom treatment was available in only some well-equipped hospitals in our country; however, in this decade, things changed. We have been producing our own antivenoms, and they are available all over the country.

The first successful antivenin serum therapy dates back to 1895. Before that, antivenom treatment was not available, and people with a weak immune system died. The first horse-derived antivenom sera, produced by a protégé of Louis Pasteur named Albert Calmette, were used by Lépinay for antivenom treatment in present-day Vietnam (1). During that time, Calmette was living in Vietnam and decided to produce an antivenom after a flood forced cobras into a village near Saigon where they bit about 40 people and killed four (2). The preparation of the first antivenom involved the separation of the serum from the blood of hyperimmunized horses. Later, it was observed that the antibodies (immunoglobulins) were responsible for the therapeutic action (3); therefore, they were purified from the plasma and used instead of crude serum. Since then, immunoglobulin fragments have played an important role in the treatment. Despite the technological development, the principle of antivenom preparation has remained the same; however, for maximum quality, the production steps were standardized by the World Health Organization (WHO) in 2008 (4); we have explained this later.

In the clinical aspect, human envenoming is a recognized medical emergency with 421,000 to 2.5 million annual cases worldwide and 20,000 to 100,000 annual deaths (5). This condition is of particular interest to our country because there are approximately 40 different types of snakes classified under six families living in Turkey, which are described as follows (6):

- Typhlopidae: 1
- Leptotyphlopidae: 1
- Boidae: 1
- Colubridae: 27
- Viperidae: 9
- Elapidae: 1

Although there are some types belonging to the Colubridae family, which contain toxins dangerous to humans, only those belonging to the Viperidae and Elapidae families pose great danger to humans. Biting characteristics of the snakes from the Colubridae family make them far from being hazardous to humans (6).

Most of the venomous snakebites in our country occur in the East Black Sea, Southeastern Anatolia, East Anatolia, and Northwest Thrace regions. Of the 10 poisonous snakes, nine belong to Viperidae and one to Elapidae families; they have been described as follows (with Turkish names in the parentheses) (6):

- V. ammodytes (Boynuzlu engerek)
- V. barani (Baran engereği)
- V. kaznakovi (Kafkas engereği)
- V. lebetina (Koca engerek)
- V. pontica (Coruh engereği)
- V. raddei (Agri engereği)

ORCID IDs of the authors: C.S. 0000-0001-8419-7426; L.T.S. 0000-0003-1218-9018; T.O.: 0000-0003-0012-6757; R.A. 0000-0002-1025-4026.
The estimated economic burden of snakebites in Turkey is unclear. However, currently, we are fortunate regarding the treatment of this disease because one of the biggest antivenom manufacturers in the world, which is a candidate member of the WHO global antivenom producers database, was established in Adiyaman, Turkey, with $5 million of investments in 2006. The factory strictly conforms to the WHO guidelines for producing antivenom. This antivenom contains a mixture of horse-origin immunoglobulin fragments effective against three snakes from the Viperidae family: \textit{Macrovipera Lebetina}, \textit{Montivipera Xanthina}, and \textit{Vipera Ammodytes}. These antivenins are found in the pharmacies of most hospitals where snake envenomation is endemic. In special circumstances, the antivenins can be obtained through communication with the National Venom Consultation Center (Ulusal Zehir Danisma Merkezi) from the hospital or via personal telephones (Phone no. 114). The center supplies the antivenins through the national pharmacy chain via land or air transportation. This is the only authorized center for antivenin production in Turkey, and it obtained authorization in 2007.

Currently, there are 45 antivenom production centers listed in the WHO database of antivenom producers. These centers strictly adhere to the WHO guidelines and are listed in the database. Vetal Serum Turkey has conformed to these guidelines and applied to be listed; we look forward for it to be listed herein in the near future.

For more than a decade, we are not only meeting our national needs but also exporting snake and scorpion antivenoms to a broad range of countries from Argentina to China. Following the listing in the WHO database, we are also expecting antivenin exportation to...
Europe and North America. We have summarized the production steps in Figure 1.

It should be considered that antivenin treatment can be more hazardous than the snake poison itself (8). Allergic reactions can be encountered during the treatment course. A cost-benefit analysis must be done before antivenin application. Adrenalin and H₁ and H₂ receptor blockers should be kept ready. Skin test is controversial before antivenin application and is generally omitted because of false-positive and negative results. Serum sickness, which is a type III hypersensitivity reaction, must be considered as a late complication on days 3-21 of treatment.

In conclusion, producing antivenoms helps us treat our patients without struggling with drug insufficiency problem, which is a common problem worldwide since the closure of big manufacturers at the end of 20th century (9). To provide a better healthcare experience for our patients, we must achieve success in more areas of pharmaceutical production, as in this study.

Peer-review: Externally peer-reviewed.


Conflict of Interest: The authors have no conflict of interest to declare.

Financial Disclosure: Preparation for publication of this article is partly supported by Turkish Neurosurgical Society.

References